Clinical trials: sponsored by Eli Lilly and Company
Neoplasms, Healthy
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein).
- Trial name
- NCT07258836
- Testing
- LY4214835
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07225556
- Testing
- LY4167586
- Where
- 2 sites in United States, Singapore
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4515100 in Healthy Participants
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines.
- Trial name
- NCT07339722
- Testing
- LY4515100 via SAD, LY4515100 via MAD, LY4515100
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of How the Body Absorbs LY3537031
The main purpose of this study is to find out how much LY3537031 gets into the blood stream and how long it takes the body to get rid of it when it is injected just under the skin in different parts of the body, and when it is…
- Trial name
- NCT07202871
- Testing
- LY3537031
- Where
- Singapore
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants.
- Trial name
- NCT06370728
- Testing
- Orforglipron, Carbamazepine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Obese
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese…
- Conditions
- Healthy, Obese, Overweight, Obesity
- Trial name
- NCT06440980
- Testing
- Orforglipron
- Where
- 7 sites in United States
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity.
- Trial name
- NCT07476118
- Testing
- Brenipatide
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in…
- Trial name
- NCT07665879
- Testing
- Eloralintide
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Adult Subjects
A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants
The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn…
- Trial name
- Willow 3 (NCT04194892)
- Testing
- Pegilodecakin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3502970 in Healthy Participants
The main purposes of this study are to determine: The safety of LY3502970 and any side effects that might be associated with it. How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT03929744
- Testing
- LY3502970, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Obese
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on…
- Trial name
- NCT05841238
- Testing
- LY3502970
- Where
- 3 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Adult Subjects
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.
- Trial name
- Willow 2 (NCT03381547)
- Testing
- Pegilodecakin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4005130 in Healthy Participants
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants.
- Trial name
- FPAB (NCT06690996)
- Testing
- LY4005130
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis (RA)
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA).
- Trial name
- NCT07258849
- Testing
- LY4213663
- Where
- 10 sites in United States, Germany
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4302814 in Healthy Participants
The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants.
- Trial name
- NCT07566338
- Testing
- LY4302814
- Where
- 2 sites in United States, Singapore
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Insufficiency, Healthy
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared…
- Trial name
- NCT05936138
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of [14C]-LY4064809 in Healthy Participants
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug.
- Trial name
- NCT07519525
- Testing
- LY4064809, [14C]-LY4064809
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Healthy
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending…
- Trial name
- NCT06657768
- Testing
- LY4006895
- Where
- 13 sites in United States, Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Insufficiency
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver.
- Trial name
- NCT07401862
- Testing
- LY3841136
- Where
- 3 sites in United States, Hungary
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company